Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of STN1010905 Ophthalmic Suspension in Meibomian Gland Dysfunction
jRCT2031210371Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in meibomian gland dysfunction (MGD) comparing STN1010905 ophthalmic suspension with Placebo ophthalmic suspension (2 arms). Primary endpoint: Sign of Meibomian glands. Started Oct 2021; status: completed.
02
Drugs
MS-R001
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on jRCT2031210371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210371.